Prof. Dr. med. Thomas Ruhstaller

Facharzt FMH für Medizinische Onkologie
Facharzt FMH für Allgemeine Innere Medizin

Kernkompetenzen

Hochspezialisiert auf die medizinisch-onkologische Behandlung von Brustkrebs und gynäkologischen Tumoren

Langjährige wissenschaftliche Tätigkeit in nationalen und internationalen Projekten der klinischen Forschung

Engagiert in nationalen gesundheitspolitischen Gremien, sowie in Fortbildung und Weiterbildung von Fachpersonen


Werdegang

Seit 06/2019                     
Partner des Brustzentrums Ostschweiz AG und Belegarzt an der Klinik Stephanshorn, St.Gallen

2006-2019                        
Stv. Chefarzt und Fachbereichsleiter der Medizinischen Onkologie am Brustzentrum des Kantonsspitals St. Gallen (KSSG)

2006-2019                        
Leitender Arzt, Medizinischen Onkologie/Hämatologie am KSSG (20%), spezialisiert für Ösophaguskarzinome

2004-2006                        
Leiter der klinisch-onkologischen Forschungsabteilung am KSSG                                       

2003-2004                        
Consultant Medical Oncologist in Carlisle, North Cumbria, England

2000-2003                        
Oberarzt Medizinsche Onkologie am Kantonsspital Münsterlingen und am KSSG (je 50%)

1997-1999                        
Facharztausbildung Medizinische Onkologie KSSG

1991- 1997                       
Facharztausbildung Allgemeine Innere Medizin

  • Chirurgie (Triemlistpital ZH)
  • Innere Medizin (Triemlispital ZH)
  • Innere Medizin (Universitätsspital ZH)
  • Pädiatrie (Kinderspital ZH)


Weitere Tätigkeiten

Seit 2011                   
Lehrauftrag an der Universität Basel, seit 2018 Inhaber einer Titularprofessur

2016-2019                 
Panel Member des “Health Services Research in Oncology and Cancer Care” (Versorgungsforschung) der Krebsforschung Schweiz

2019                           
Mitglied der Arbeitsgruppe «Tumorboard» im Nationalen Krebsprogramm des Bundes

seit 2017                    
Vorstandsmitglied des «Swiss Hyperthermia Network», Zusammenschluss der Zentren für Hyperthermie-Behandlungen im Auftrag des BAG

2013-2019                 
Mitinitiator und Moderator der Initiative «Chicago in the Mountains»: Parallele Übertragung des amerikanischen Onkologie Kongresses (ASCO) in ein Schweizer Berghotel

2011- 2019                
Mitglied des Programmkomitees des Jahreskongresses der Deutschen Gesellschaft für Hämatologie/Onkologie (DGHO), die schweizerischen und österreichischen Gesellschaften sind mitbeteiligt

2011 – 2017              
Präsident der nationalen Forschungsgruppe «Breast Cancer» der Schweizerischen Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK)

2011 – 2017              
Board Member in der «Swiss Academy of Multidisciplinary Oncology» (SAMO), einer nationalen Fortbildungsorganisation

2013 -2015                
gewähltes Mitglied der Arbeitsgruppe der SAKK für Beratung der IVHSM (Interkantonale Vereinbarung der Hochspezialisierten Medizin)

seit 2011                    
Associate Editor des BMC Cancer, peer-reviewed, aktueller 5y-Impact factor: 3.645

Seit 2006                   
Mitorganisator von jährlichen Fortbildungen zum Thema Brustkrebs (St.Galler Senologie Symposium, Post-San Antonio-Meeting, Deso-Fortbildungen, etc.)

seit 2001                    
Leitung aller nationalen, interdisziplinären Forschungsaktivitäten beim Ösophaguskarzinoms (mehrere nationale Phase-ll-Studien und eine internationale Phase-lll-Studie) im Rahmen der SAKK

 

Mitgliedschaften

SGMO Schweizerische Gesellschaft für Med. Onkologie

SGS Schweizerische Gesellschaft für Senologie

SAKK Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung

IBCSG International Breast Cancer Study Group

ESMO European Society for Medical Oncology

ASCO American Society for Clinical Oncology

FMH Foederatio Medicorum Helveticorum

Ärzteverein der Stadt St. Gallen

Ärztegesellschaft des Kantons St. Gallen

 

Publikationsliste

Nur Publikationen aus “peer-reviewed journals” (zitiert im PubMed)

2019

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomized phase 3 trial

Karin Ribi, Weixiu Luo, Marco Colleoni, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Vincenzo Di Lauro, Henry Gómez, Thomas Ruhstaller, Ehtesham Abdi, Laura Biganzoli, Bettina Müller, Annelore Barbeaux, Marie-Pascale Graas, Manuela Rabaglio-Poretti, Prudence Francis, Theodoros Foukakis, Olivia Pagani, Claudio Graiff, Daniel Vorobiof, Rudolf Maibach, Angelo Di Leo, Richard Gelber, Aron Goldhirsch, Alan Coates, Meredith Regan, and Juerg Bernhard

Br J Cancer. 2019 Apr 10. doi: 10.1038/s41416-019-0435-4. [Epub ahead of print]

 

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores.

Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli P.

Ther Adv Med Oncol. 2019 Jan 2;11:1758835918818351

 

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women with Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, Maj-Britt Jensen, Bent Ejlertsen, Evandro de Azambuja, Patrick Neven, Istv´an L´ang, Erik Hugger Jakobsen, Laurence Gladieff, Herv´e Bonnefoi, Vernon J., Harvey, Simon Spazzapan, Carlo Tondini, Lucia Del Mastro, Corinne Veyret, Edda Simoncini, Lorenzo Gianni, Christoph Rochlitz, Elena Kralidis, Khalil Zaman, Jacek Jassem, Martine Piccart-Gebhart, Angelo Di Leo, Richard

D. Gelber, Alan S. Coates, Aron Goldhirsch, Beat Thürlimann, and Meredith M. Regan, for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group

J Clin Oncol. 2019 Jan 10;37(2):105-114.

 

2018

Tailored Axillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter randomized phase III trial.

Guido Henke, MD; Michael Knauer, MD PhD; Karin Ribi, PhD; Stefanie Hayoz, PhD; Marie-Aline Gérard, PhD; Thomas Ruhstaller, MD; Daniel R Zwahlen, MD; Simone Münst Soysal, MD; Markus Ackerknecht, PhD; Hanne Hawle, MD; Florian Fitzal, MD; Michael Gnant, MD; Zoltan Matrai, MD PhD; Bettina Ballardini, MD; Andreas Gyr, MA; Christian Kurzeder, MD; Walter Paul Weber, M.D.

Trials. 2018 Dec 4;19(1):667

 

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W, Eisterer W, Hawle H, Mariette C, Hess V, Mingrone W, Montemurro M, Girschikofsky M, Schmidt SC, Bitzer M, Bedenne L, Brauchli P, Stahl M; Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch.

Ann Oncol. 2018 Jun 1;29(6):1386-1393

 

Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of

tumor cell stemness

Maximilian Boesch, Lucas Onder, Hung-Wei Cheng, Mario Novkovic, Urs Mörbe, Sieghart Sopper, Guenther Gastl, Wolfram Jochum, Thomas Ruhstaller, Michael Knauer, Burkhard Ludewig

Oncoimmunology. 2018 Jan 3;7(4)

 

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC

ESMO Open. 2018 Aug 20;3(5):e000368

 

Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial.

Weber WP, Tausch C, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer M; Swiss Group for Clinical Cancer Research (SAKK).

Ann Surg Oncol. 2018 Jun 8. doi: 10.1245/s10434-018-6556-9. (Epub ahead of print)

 

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137

 

Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu.

Ruhstaller T, Langer R, Thuss-Patience P, Eisterer W, Stahl M.

Ann Oncol. 2018 Jul 9. doi: 10.1093/annonc/mdy238. [Epub ahead of print] No abstract available.

 

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M.

Breast Cancer Res Treat. 2018 Jul;170(2):351-360 V

 

Vitamin D levels in Swiss breast cancer survivors

Baumann M, Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B

Swiss Med Wkly. 2018 Jan 16;148:w14576

 

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators

Lancet Oncol. 2018 Jan;19(1):127-138

 

2017

Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of

tumor cell stemness

Maximilian Boesch, Lucas Onder, Hung-Wei Cheng, Mario Novkovic, Urs Mörbe, Sieghart Sopper, Guenther Gastl, Wolfram Jochum, Thomas Ruhstaller, Michael Knauer & Burkhard Ludewig

OncoImmunology, DOI: 10.1080/2162402X.2017.1414129

 

Recurrence Patterns and Long-Term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer.

Steffen T, Dietrich D, Schnider A, Kettelhack C, Huber O, Marti WR, Furrer M, Gloor B, Schiesser M, Thierstein S, Brauchli P, Ruhstaller T; Swiss Group for Clinical Cancer Research (SAKK).

Ann Surg. 2017 Jul 24. doi: 10.1097/SLA.0000000000002435. [Epub ahead of print

 

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.

Regan MM, Walley BA, Francis PA, Fleming GF, Lang I, Gomez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O.

Ann Oncol 0: 1-8, 2017. First published online July 29, 2017 (IBCSG 24-02 and 25-02) (Journal Impact Factor 11.855).

 

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, for the Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer, 2017 Apr 13;17(1):265

 

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos RV, Zaman K, Goldhirsch A;

Swiss Group for Clinical Cancer Research (SAKK)..

Ann Oncol. 2017 Feb 1;28(2):305-312

 

2016

Christoph Rochlitz , Martin Bigler, Roger von Moos, Jürg Bernhard, Klazien Matter-Walstra, Andreas Wicki, Khalil Zaman, Sandro Anchisi, Marc Küng, Kyung-Jae Na, Daniela Bärtschi, Markus Borner, Tamara Rordorf, Daniel Rauch, Andreas Müller, Thomas Ruhstaller, Marcus Vetter, Andreas Trojan, Ursula Hasler-Strub, Richard Cathomas, and Ralph Winterhalder on behalf of the Swiss Group for Clinical Cancer Research (SAKK)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs.bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

BMC Cancer (2016) 16:780

 

Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Breast Cancer Res Treat. 2016 Jul 2. [Epub ahead of print].

 

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ

Palbociclib as a first-line treatment in oestrogen receptor-positive,

HER2-negative, advanced breast cancer not cost-effective with current

pricing: a health economic analysis of the Swiss Group for Clinical Cancer

Research (SAKK).

Breast Cancer Res Treat, 158 (1),51-7

 

Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perelló A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

J Clin Oncol. 2016 May 10;34(14):1601-10

 

Cattin S, Fellay B, Pradervand S, Trojan A, Ruhstaller T, Rüegg C, Fürstenberger G.

Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.

Oncotarget. 2016 Mar 8;7(10):11137-50    (IF 5.008)

 

2015

Zsuzsanna Varga, Estelle Cassoly, Qiyu Li, Christian Oehlschlegel, Coya Tapia,

Hans Anton Lehr, Dirk Klingbiel, Beat Thürlimann, Thomas Ruhstaller

Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A

Retrospective Analysis of the SAKK 28/12 Study

PLoS One. 2015 Apr 17;10(4):e0123435

 

Jürg Bernhard, Weixiu Luo, Karin Ribi, Marco Colleoni, Harold J Burstein, Carlo Tondini, Graziella Pinotti, Simon Spazzapan, Thomas Ruhstaller, Fabio Puglisi, Lorenzo Pavesi, Vani Parmar, Meredith M Regan, Olivia Pagani, Gini F Fleming, Prudence A Francis, Karen N Price, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Barbara A Walley

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Lancet Oncol 2015; 16:848-858

 

Paul Martin Putora, Laurent Bedenne, Wilfried Budach, Wolfgang Eisterer, Ate Van Der Gaast, Robert Jäger, J. Jan B. Van Lanschot, Christophe Mariette, Annelies Schnider, Michael Stahl and Thomas Ruhstaller

Oesophageal cancer: exploring controversies overview of experts’ opinions of Austria, 4 Germany, France, Netherlands and Switzerland

Radiat Oncol. 2015 May 21;10:116

 

2014

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

N Engl J Med. 2014 Jul 10;371(2):107-18

 

Templeton A, Ribi K, Surber C, Sun H, Hsu Schmitz S, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann B, Ruhstaller T

Prevention of palma-plantar erythrodysesthesia with and antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)

The Breast 23 (2014) 244-249

 

Stahl M, Ruhstaller T.

Combined modality treatment of oesophageal cancer (Multimodale Therapie des Ösophaguskarzinoms).

Internist (Berl). 2014 Jan;55(1):7-8, 10-4

 

2013

Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF.

Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

Ann Oncol. 2013 Oct;24(10):2543-8.

 

Templeton AJ, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T.

Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors.

BMC Cancer. 2013 Mar 25;13:153.

 

2012

Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F; First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel.

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

Eur J Cancer. 2012 Nov;48(16):2941-53.

 

2011

Bolla D, Ruhstaller T, Diener PA, Lang F, Hornung R

Cervical and vaginal cancer in a woman with chronic graft-versus-host disease

Int J Gynaecol Obstet 2011 Aug; 114(2): 159-60

 

Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B; Swiss Group for Clinical Cancer Research (SAKK)

Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)

Endocr Relat Cancer. 2011 Mar 9;18(2):257-64

 

Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V

Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)

J Clin Oncol. 2011 Feb 20;29(6):626-31

 

Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; on behalf of the Swiss Group for Clinical Cancer Research (SAKK)

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)

Ann Oncol. 2011 Jan;22(1):80-5

 

2010

von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

Onkologie 2010;33(6):295-299

 

Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, Wilke H, Archer C, Kurek R, Beadman C, Oates J

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Ann Oncol. 2010 Nov;21(11):2213-9

 

Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Von Moos R, Kaspar C, Lohri A, Lombriser N, von Briel C, Köberle D, Popescu R

Intense Therapy in Patients with Locally Advanced Esophageal Cancer beyond hope for surgical cure: Prospective, Multicenter Phase II Trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)

Onkologie 2010;33(5):222-8

 

Jost C, Binek J, Schuller JC, Bauerfeind P, Metzger U, Werth B, Knuchel J, Frossard

J-L, Bertschinger P, Brauchli P, Meyenberger C, Ruhstaller T

Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective, multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)

Gastrointest Endos 2010;71(7):1114-1121

 

2009

 Ribi K, Koeberle D, Schuller JC, Honegger H, Roth A, Hess V, Moosmann P, von Moos R, Borner M, Lombriser N, Pestalozzi B, Ruhstaller T

Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced oesophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?

Support Care Cancer 2009;17:1109-16

 

Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B

Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study

Oncology 2009;76(2):142-8

 

Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R; Swiss Group for Clinical Cancer Research (SAKK)

Multicenter Phase ll Trial of Preoperative Induction Chemotherapy Followed by Chemoradiation with Docetaxel and Cisplatin for Locally Advanced Esophageal Carcinoma (SAKK 75/02)

Ann Oncol 2009 Sep; 20(9):1522-8

 

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R

Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?

Support Care Cancer 2009 Okt; 18(19): 1263-70

 

Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, Hany T, Cescato-Wenger C, Brauchl Pi, Zünd M, Pestalozzi PC, Caspar C, Albrecht S, von Moos R, Ruhstaller T

Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: Results of a prospective multi-center trial (SAKK 75/02)

Onkologie 2009; 32(12):724-30

 

Spirig C, Omlin A, D'Addario G, Loske KD, Esenwein P, Geismar JH, Ruhstaller T

Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report

J Med Case Reports 2009 Nov 2;3:93

 

2008

 Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

Lancet Oncol 2008 Feb;9(2):132-8

 

Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M

Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer

Br J Cancer 2008 Apr 8;98(7):1204-9

 

Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

Ann Oncol 2008 Jul;19(7):1288-92

 

Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized

Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

J Clin Oncol 2008 Aug 1;26(22):3695-701

 

Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research

Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research

J Clin Oncol 2008 Aug 1;26(22):3702-8

 

Grimm B, Padberg B, Ruhstaller T, Fleisch F, von Moos R

Fatal herpes simplex virus (HSV) hepatitis in a patient with esophageal cancer under radiochemotherapy

Onkologie 2008 Nov;31(11):620-2

 

Greuter S, Schmid F, Ruhstaller T, Thuerlimann B

Bevacizumab-associated osteonecrosis of the jaw

Ann Oncol 2008 Dec;19(12):2091-2

 

2007

 Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

J Clin Oncol 2007 Jun 1;25(16):2212-7

 

Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, Ruhstaller T, Glaus A, Böhme C

Endocrine symptom assessment in women with breast cancer: what a simple "yes" for the patients mean

Support Care Cancer 2007 Dec;15(12):1349-56

 

Salzberg M, Thurlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, von Moos R

Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Communitiy-Based Observation Study

Oncology 2007;72(3-4):147-51

 

Ruhstaller T, Thuerlimann B, Koeberle D, von Moos R

Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma ?

J Clin Oncol 2007 Sep 1:4025-4026

 

2006

von Moos R, Ruhstaller T, Fretz C

CASE 3. Red Eye in Sjögren’s Syndrome Due to Underlying Mucosa-Associated Lymphoid Tissue Lymphoma

J Clin Oncol 2006 Feb 20;24(6):1011-3

 

Glaus A, Boehme Ch, Thürlimann B, Ruhstaller T, Hsu Schmitz SF, Morant R, Senn HJ, von Moos R

Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment

Ann Oncol 2006 May;17(5):801-6

 

Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ

The Multidisciplinary Meeting – an indispensable aid to communicate between different specialities

Eur J Cancer 2006 Oct;42(15):2459-62

 

Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group

J Clin Oncol 2006 Jul 20;24(21):3394-400

 

2005

Früh M, Ruhstaller T, Neuweiler J, Cerny T

Resection of skin metastases of gastric carcinoma with long-term follow-up: an unusual clinical presentation

Onkologie 2005 Jan;28(1):38-40

 

Seium Y, Stupp R, Ruhstaller T, Gervaz P, Mentha G, Philippe M, Allal A, Trembleau C, Bauer J, Morant R, Roth AD

Oxaliplatin combined with irinotecan and 5FU/leucovorin (OCFL) in metastatic colorectal cancer: a phase l-ll study

Ann Oncol 2005 May;16(5):762-6

 

Ruhstaller T, Mueller A, Koeberle D, Thuerlimann B

Is there really enough evidence to abandon surgery after radio-chemotherapy in esophageal cancer ?

J Clin Oncol 2005 Nov 20;23(33):8547-8

 

2000

Ruhstaller T, Amsler U, Cerny T

Rituximab: Active treatment of central nervous system involvement by non-Hodgkin’s lymphoma

Ann Oncol 2000 Mar;11(3):374-5